Celgene's Revlimid falls short at NICE; Omnicare to pay $120M in kickback probe;

@FiercePharma: Roche is putting $900M into biologics manufacturing, but turning to Samsung for some of its drugs. News | Follow @FiercePharma

@CarlyHFierce: Here's FiercePharmaManufacturing's take on McKesson's Celesio buyout. More | Follow @CarlyHFierce

> The U.K.'s cost-effectiveness watchdogs refused to back Celgene's ($CELG) blood cancer drug Revlimid for a new use in a rare bone marrow disorder. Report

> Omnicare agreed to pay $120 million to settle a U.S. kickback lawsuit, which alleges that the pharmacy services provider gave nursing homes heavily discounted drugs in exchange for patient referrals. Report

> Cubist Pharmaceuticals ($CBST) posted third-quarter earnings of 41 cents per share, far short of the expected 55 cents, because of higher expenses; sales rose by 12% to $266 million. Report

> The FDA said it's completing its phase-out of all drug inhalers containing CFCs by Dec. 31 to comply with an international treaty. Release

> Sanofi ($SNY) moved all its human resources operations in more than 100 countries into the cloud to allow for new global processes and data analytics. Report

> China's Sinopharm said its 9-month net profit rose 17.5%. Report

> GlaxoSmithKline ($GSK) is eyeing a new advertising agency for its global digital advertising. Report

> Novo Nordisk ($NVO) said it's worried about illegal online sales of its growth hormone, some of which probably isn't genuine. Report

> The U.K.'s National Health Service hired Simon Stevens to take over as CEO next year; Stevens currently heads up the global health division of U.S.-based insurer UnitedHealth. Report

> As it prepares to be acquired by Perrigo ($PRGO), Elan ($ELN) posted earnings before interest and taxes of $12.1 million and said it has $1.9 billion in cash on hand. Report

Medical Device News

@FierceMedDev: UPDATED: Boston Scientific to slash up to 1,500 more jobs even as Q3 numbers improve. Story | Follow @FierceMedDev

@MarkHFierce: Check out this week's FierceDiagnostics newsletter | Follow @MarkHFierce

@MichaelGFierce: Layered nanoparticles deliver RNA, chemo for one-two punch. Item from FierceDrugDelivery | Follow @MichaelGFierce

> Med tech VC Versant raising $250M new fund amid sluggish market. Story

> Vitamin B2 may help build a safer 3-D medical implant. Item

> Zimmer lowers outlook as profits slide despite ortho growth. Report

> DeCODE spinout raises $15M to bring gene sequencing into daily Dx. Article

Biotech News

@FierceBiotech: ICYMI yesterday: The top 10 biotech IPOs of 2013. Special report | Follow @FierceBiotech

@JohnCFierce: Rigel sinks after adding another trial failure to its losing streak. News | Follow @JohnCFierce

@DamianFierce: Repros tanks as FDA scrutiny of testosterone drug pushes back NDA date. ICYMI yesterday | Follow @DamianFierce

@EmilyMFierce: ICYMI: Takeda, Hopkins developing new pancreatic cancer drugs. More from FierceBiotech Research | Follow @EmilyMFierce

> Armed-antibody successes inspire a burst of new building projects, industry deals. More

> Troubled Merck shrugs off fresh doubts about late-stage heart drug. Article

> Bristol-Myers exec sentenced to a year in prison on insider trading scheme. Report

> AstraZeneca plans to shutter lab, ax staffers. Item

Pharma Manufacturing News

@EricPFierce: Samsung, which has worked on a biosimilar of Rituxan, has a new deal to make biologics for Roche. Article | Follow @EricPFierce

> Stolen Novo growth hormone sold on Internet. Item

> McKesson makes $8.3B move on Europe. Story

> Actis invests $48M in API maker Symbiotec. News

> Hospira unveils new quality lab at troubled plant. More

Vaccines News

> Finnish team talks up prospects of Type 1 diabetes vaccine. Report

> Study finds herd immunity protects babies against whooping cough. More

> Meta-analysis links flu vaccine to lower risk of heart attack and stroke. Article

> Timing of first measles vaccine dose linked to effectiveness. Item

> Taliban anti-vaccine push raises risk of polio outbreak. Story

And Finally... Prostate cancer radiation therapy is more commonly prescribed by urologists who own their own equipment to provide the treatment. Report